英国剑桥大学的研究团队近日在帕金森病药物研发领域取得了重大突破，他们运用人工智能（AI）技术，成功将药物设计的速度提升了十倍，极大地缩短了新疗法的研发周期。这一创新性的研究方法被发表在最新一期的《自然·化学生物学》杂志上。
据科技日报报道，研究人员针对帕金森病的关键特征蛋白——α-突触核蛋白，设计了一种基于AI的智能策略。这种策略能够高效地识别出能够阻止该蛋白聚集的小分子，从而有望阻止帕金森病的进展。传统药物筛选过程耗时且成本高昂，但借助AI技术，研究团队不仅加快了初始筛选的进程，还将成本降低了整整千分之一。
这一突破性的进展预示着帕金森病潜在疗法的研发速度将显著提升，为全球数百万帕金森病患者带来了新的希望。英国剑桥大学的研究成果再次证明，AI技术在医疗领域的应用具有巨大的潜力，能够推动科学界更快地解决复杂医学问题，改善人类健康。
英语如下：
**News Title:** “Cambridge University Accelerates Parkinson’s Drug Development Tenfold with AI Technology”
**Keywords:** AI制药, 帕金森疗法, 剑桥研究
**News Content:** Researchers at the University of Cambridge in the United Kingdom have recently made a significant breakthrough in the development of Parkinson’s disease drugs. By employing artificial intelligence (AI) technology, they have successfully sped up the drug design process by a factor of ten, significantly reducing the time required to develop new therapies. This innovative research approach has been published in the latest issue of _Nature Chemical Biology_.
According to _Science and Technology Daily_, the team targeted the key Parkinson’s disease protein, α-synuclein. They devised an AI-driven intelligent strategy that efficiently identifies small molecules capable of preventing the protein from aggregating, potentially halting the progression of the disease. Traditional drug screening processes are time-consuming and costly, but with AI, the research team not only accelerated the initial screening but also reduced costs by one thousandth.
This groundbreaking advance signals a substantial acceleration in the development of potential Parkinson’s treatments, offering new hope to millions of patients worldwide. The University of Cambridge’s accomplishment underscores the immense potential of AI in the medical field, demonstrating its ability to propel the scientific community in solving complex medical issues more rapidly and improving human health.
【来源】http://digitalpaper.stdaily.com/http_www.kjrb.com/kjrb/html/2024-04/22/content_570458.htm?div=-1
Views: 1